Reference : Identification of SOCS2 and SOCS6 as biomarkers in human colorectal cancer.
Scientific journals : Article
Human health sciences : Oncology
http://hdl.handle.net/10993/18264
Identification of SOCS2 and SOCS6 as biomarkers in human colorectal cancer.
English
Letellier, Elisabeth mailto [University of Luxembourg > Faculty of Science, Technology and Communication (FSTC) > Life Science Research Unit]
Schmitz, Martine mailto [University of Luxembourg > Faculty of Science, Technology and Communication (FSTC) > Life Science Research Unit]
Baig, Komal mailto [University of Luxembourg > Faculty of Science, Technology and Communication (FSTC) > Life Science Research Unit]
Beaume, Nicolas mailto [University of Luxembourg > Faculty of Science, Technology and Communication (FSTC) > Life Science Research Unit]
Schwartz, C. [> >]
Frasquilho, S. [> >]
Antunes, L. [> >]
Marcon, N. [> >]
Nazarov, P. V. [> >]
Vallar, L. [> >]
Even, J. [> >]
Haan, Serge mailto [University of Luxembourg > Faculty of Science, Technology and Communication (FSTC) > Life Science Research Unit]
2014
British journal of cancer
111
4
726-35
Yes (verified by ORBilu)
International
0007-0920
1532-1827
England
[en] Colorectal cancer ; SOCS ; Biomarker
[en] BACKGROUND: Over the past years, some members of the family of suppressor of cytokine signalling (SOCS) proteins have emerged as potential tumour suppressors. This study aimed at investigating the clinical significance of SOCS proteins in colorectal carcinoma (CRC). METHODS: We integrated publicly available microarray expression data on CRC in humans, analysed the expression pattern of SOCSs and assessed the predictive power of SOCS2 and SOCS6 for diagnostic purposes by generating receiver operating characteristic curves. Using laser microdissected patient material we assessed SOCS expression on RNA and protein levels as well as their methylation status in an independent CRC patient cohort. Finally, we investigated the prognostic value of SOCS2 and SOCS6. RESULTS: The meta-analysis as well as the independent patient cohort analysis reveal a stage-independent downregulation of SOCS2 and SOCS6 and identify both molecules as diagnostic biomarkers for CRC. We demonstrate a different methylation pattern within the SOCS2 promoter between tumour tissue and normal control tissue in 25% of CRC patients. Furthermore, early CRC stage patients with low expression of SOCS2 display significantly shorter disease-free survival. CONCLUSIONS: Our data offers evidence that SOCS2 and SOCS6 levels are reduced in CRC and may serve as diagnostic biomarkers for CRC patients.
http://hdl.handle.net/10993/18264

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Limited access
Letellier et al_British journal of Cancer_2014_SOCS2 and SOCS6 as biomarkers for CRC.pdfPublisher postprint1.75 MBRequest a copy

Additional material(s):

File Commentary Size Access
Limited access
Letellier et al_British journal of Cancer_2014_SOCS2 and SOCS6 as biomarkers for CRC_supplements.pdfsupplemental data242.87 kBRequest a copy

Bookmark and Share SFX Query

All documents in ORBilu are protected by a user license.